PeptideStack
5.2kquestions
20kanswers
220users

What is the dead-space loss per draw with a 27G needle at 8 mg/mL?

Asked 29 Mar 2025Modified 12 months agoViewed 19k times
36

Concretely: a 27G needle · 8 mg/mL.

I want the working, not the result — I need to be able to redo it with different numbers.

I care about the precision as well as the value — I want to know how many figures are real.

Is my approach right even if my number is wrong?

dead-space
dead-space

The volume trapped in the syringe hub and needle after the plunger bottoms out. It is small in absolute terms and large as a fraction of a small…

110 questions
insulin-syringe
insulin-syringe

U-100 and U-40 insulin syringes as measuring instruments. A U-100 syringe is graduated in insulin units where 100 units equals 1 mL, so one unit…

268 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
shareeditfollowflag
DZ
askedDr_Marek_Zielinski39k3829 Mar 2025

5 Answers

Accepted answer first, then by votes
-3

Accepted answer

Start from the worked arithmetic: a 10 mg vial reconstituted with 2 mL gives 5 mg/mL. One hundred microliter draws are 0.5 mg each. At 84 µL dead space per draw, half your vial disappears into the hub.

The needle lumen volume is under a microlitre in a typical fine-gauge configuration, so the needle is not the problem.

Configuration A — 1 mL luer-lock plus detachable needle, dead space 84 µL: each draw removes 100 + 84 = 184 µL. Draws available from 2,000 µL = 2000 / 184 = 10.87, so 10 full draws.

The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.

The switch nearly doubles your vial, which is better than most other optimisations combined.

shareimprove this answerflag
LD
answered · acceptedloss_on_drying47k13817 Jul 2025
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
13

A fixed-needle insulin syringe holds roughly 3 to 5 µL dead space and costs the same as a luer-lock syringe with 35 to 100 µL dead space.

Delivered peptide = 10 x 0.5 mg = 5.0 mg. Lost to dead space = 10 x 84 µL = 840 µL x 0.005 = 4.2 mg. Yield = 50 per cent.

To be exact about it, the complete rule: fix the syringe architecture first, and then the reconstitution volume becomes a free choice you can make on stability grounds rather than on economics.

I would not underestimate the dead-space cost when calculating your true cost per dose.

Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.

shareimprove this answerflag
SC
answeredstopper_core50k13830 Mar 2025
4Useful. I have added the accept threshold suggestion to my own notes. – h_pergande 5 months ago
add a comment
9

The single most important fact about dead space is that it is almost entirely in the hub cone, not in the needle, which is why changing needle gauge or length barely changes your losses.

Low-dead-space syringe designs either have the needle bonded directly to the barrel — a fixed-needle syringe, which is the cheapest route — or add a moulded projection on the plunger tip that fills the luer cone.

It helps to be literal here: the luer cone of the syringe plus the needle's own plastic hub accounts for the vast majority of the dead space.

Worth noting: draw size matters enormously — the smaller your draws, the more the syringe architecture matters.

If cost matters, this is the first thing to change, not the last.

shareimprove this answerflag
IB
answeredines_brandt93k2483 Jun 2025
3I tested this on two lots and got the same answer, so at least it reproduces. – loss_on_drying 2 months ago
2The timing signature is the useful part. Everything else is confounded. – Dr_Yusuf_Adeyemi 24 days ago
add a comment
9

Before anything else: understand that dead space is a property of the syringe architecture, not of the needle gauge.

At 5 mg/mL that is 15 to 25 µg lost per draw on the insulin syringe and 175 to 500 µg on the luer-lock — which over ten draws is the difference between losing a rounding error and losing half a milligram.

Syringe residual volume has been measured properly, mainly in the infection-control literature, with a median residual of about 84 µL for a conventional 1 mL syringe with a detachable needle and roughly 2 µL for a fixed-needle low-dead-space design.

The switch nearly doubles your vial, which is better than most other optimisations combined.

edited 18 Jul 2025 by thabo_maseko — updated for the 2026 guidance change

shareimprove this answerflag
TM
answeredthabo_maseko20k2725 Jun 2025
Confirming from the other direction: I did the wrong thing and got exactly the predicted outcome. – two_two_micron 6 months ago
Is there a reason to prefer the second method over the first, other than cost? – k_szabo 7 months ago
add a comment
7

The part that matters: the short answer is that dead space is small in absolute terms and huge as a fraction of a small dose, which is why it feels like a rounding error and behaves like a systematic loss.

Dead space quantified: a fixed-needle insulin syringe holds roughly 3 to 5 µL in the hub and needle after the plunger bottoms out. A luer-lock syringe with a detachable needle holds 35 to 100 µL depending on the hub design.

Published inter-laboratory comparisons of dead-space measurements on identical syringes show good agreement, suggesting the numbers are reliable.

Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.

shareimprove this answerflag
EV
answeredesther_vandeVelde49k386 Jul 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.